Search results
Results from the WOW.Com Content Network
Pantoprazole, sold under the brand name Protonix, among others, is a medication used for the treatment of stomach ulcers, short-term treatment of erosive esophagitis due to gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger–Ellison syndrome.
Associations of PPI use and cardiovascular events have also been widely studied but clear conclusions have not been made as these relative risks are confounded by other factors. [ 55 ] [ 56 ] PPIs are commonly used in people with cardiovascular disease for gastric protection when aspirin is given for its antiplatelet actions.
Pantoprazole was first prepared in April 1985 by a small group of scale-up chemists. It is a dimethoxy-substituted pyridine bound to a fluoroalkoxy substituted benzimidazole. [5] Pantoprazole sodium is available as gastroresistant or delayed release tablets and as lyophilized powder for intravenous use.
(Even though it’s limited to diabetes patients, Ozempic is already one of the top 10 selling drugs in Medicare Part D.) Expert analyses have come up with radically different price tags.
The role of antibiotic in the therapies is to eradicate H. pylori, while the action of PPI is to reduce gastric acid secretion. The anti-ulcer dosing regimens generally repair the injury of gastric mucosal layer in PUD. Examples of dosing regimen: [17] Amoxicillin + clarithromycin + PPI; Bismuth subsalicylate + tetracycline + metronidazole + PPI
With home prices still on the rise in every region of the U.S., 63% of homeowners say they'd rather remodel their homes than move to renovated homes, according to an October survey by Clever Real...
Lilly answered with Mounjaro and Zepbound, approved in 2022 and 2023 for diabetes and weight loss, respectively. They use the active ingredient tirzepatide, which mimics not just GLP-1 but another ...
The American Association of Clinical Endocrinologists (AACE), which provides clinical practice guidelines for management of diabetes, retains thiazolidinediones as recommended first, second, or third line agents for type 2 diabetes mellitus, as of their 2019 executive summary, over sulfonylureas and α-glucosidase inhibitors.